Published On: Wed, Oct 19th, 2016

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Updated Broker Ratings


A number of investment brokers have recently updated their price targets on shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT).

Most recent broker ratings

10/14/2016 – Intercept Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 159 price target on the stock.

10/11/2016 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Wedbush. They now have a USD 239 price target on the stock.

09/20/2016 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Robert W. Baird. They now have a USD 332 price target on the stock.

08/18/2016 – Intercept Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 200 price target on the stock.

08/05/2016 – Intercept Pharmaceuticals, Inc. had its “sell” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 60 price target on the stock.

08/05/2016 – Intercept Pharmaceuticals, Inc. was downgraded to “sell” by analysts at Laidlaw. They now have a USD 105 price target on the stock.

08/04/2016 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 218 price target on the stock.

06/01/2016 – Intercept Pharmaceuticals, Inc. had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 205 price target on the stock.

05/31/2016 – Intercept Pharmaceuticals, Inc. had its “underweight” rating reiterated by analysts at Morgan Stanley. They now have a USD 80 price target on the stock.

05/31/2016 – Intercept Pharmaceuticals, Inc. had its “market outperform” rating reiterated by analysts at JMP Securities. They now have a USD 200 price target on the stock.

05/31/2016 – Intercept Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 128 price target on the stock.

05/31/2016 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 215 price target on the stock.

05/31/2016 – Intercept Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 200 price target on the stock.

05/31/2016 – Intercept Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Needham & Company. They now have a USD 350 price target on the stock.

04/08/2016 – Intercept Pharmaceuticals, Inc. had its “underperform” rating reiterated by analysts at Bank of America Merrill Lynch. They now have a USD 144 price target on the stock.

The share price of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) was up +1.68% during the last day of trading, with a day high of 142.10. 361640 shares were traded during the last session.

The stock’s 50 day moving average is 154.71 and its 200 day moving average is 151.81. The stock’s market capitalization is 3.48B. Intercept Pharmaceuticals, Inc. has a 52-week low of 89.76 and a 52-week high of 217.99.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.